Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 versus SAVAYSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 versus SAVAYSA.
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% vs SAVAYSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing fibrin clot formation and extension.
Direct inhibitor of factor Xa, thereby decreasing thrombin generation and fibrin clot formation.
Loading dose: 5000 units IV bolus, then continuous IV infusion at 12,000-18,000 units/24h (10-15 units/kg/h). Adjust to target aPTT 60-80 seconds.
5 mg orally twice daily for nonvalvular atrial fibrillation; 5 mg orally twice daily for venous thromboembolism treatment after initial parenteral anticoagulation for 5-10 days.
None Documented
None Documented
The terminal elimination half-life of heparin is dose- and concentration-dependent, averaging 1-2 hours after intravenous administration. At therapeutic doses, the half-life is approximately 1.5 hours; with higher doses, it can extend to 2.5-3 hours. The half-life is prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life is 10-14 hours; in healthy subjects, mean half-life is approximately 10 hours. Clinically, this supports once-daily dosing. Half-life is prolonged in renal impairment (e.g., up to 17 hours in severe renal impairment).
Heparin is eliminated primarily via the reticuloendothelial system and liver, with renal excretion of metabolites accounting for approximately 50-60% of the dose. A small fraction (up to 5%) is excreted unchanged in urine. No significant biliary or fecal elimination.
Eliminated primarily via renal excretion of unchanged drug (approximately 82% of an oral dose is excreted in urine as edoxaban). Fecal/biliary excretion accounts for about 8%. Minor metabolism (<10%) via hydrolysis (mediated by carboxylesterase 1) and conjugation, with metabolites excreted renally or in feces.
Category A/B
Category C
Anticoagulant
Anticoagulant, Direct Factor Xa Inhibitor